Stereotactic ablative therapy (SABR) has proven effective in treating many types of primary tumors. Robert Timmerman, M.D., discusses how SABR might improve survival rates for patients with metastatic cancer.
Cancer death rates have dropped nearly 30% since 1991, and more that 2% between 2016 and 2017 alone – the biggest one-year drop on record. The driver has been precision medicine, an approach that focuses on personalization and collaboration. Learn more now.
